Leo Pharma to Acquire Bayer Prescription Dermatology Portfolio

Leo Pharma has agreed to acquire Bayer’s global prescription dermatology unit for an undisclosed price, the companies said, in a deal that expands the buyer’s focus on skin drugs.The portfolio that Leo is acquiring from Bayer includes branded topical prescription treatments for acne (Skinoren®), fungal skin infections (Travogen® and Travocort®) and rosacea (Finacea®), and a range of topical steroids (Advantan®, Nerisona®, and Desonate®).Not included in the